Biology Driven Treatment Strategy for Breast Cancer
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Methodology, Drug and Device Discovery".
Deadline for manuscript submissions: closed (31 July 2021) | Viewed by 328
Special Issue Editor
Interests: medical oncology; breast cancer; clinical trials; translational research for breast cancer
Special Issue Information
Dear Colleagues,
Currently, breast cancer is classified by hormone receptor, HER2, and Ki67 status. These biomarkers are predictors of response to treatment, and treatment options such as endocrine therapy and anti-HER2 therapy are selected according to the biomarkers' expression status. However, when patients become resistant to these targeted therapies or no biomarkers are expressed, chemotherapy without specific predictors of efficacy is currently the treatment of choice. Many biomarkers such as TROP-2, HER3, PD-L1, and germline BRCA1/2 mutations have been developed, and targeted therapies for each biomarker have been applied in the clinical setting. Optimal breast cancer treatment using these biomarkers will be discussed.
Dr. Akihiko Shimomura
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Breast cancer
- Biomarkers
- Treatment
- Targeted therapies
- Chemotherapy
- Expression
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
